SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Unique contrast freedom hope leadership concept, red man looking at sky from the crowd, surreal painting illustration
Tariffs
Rare Disease, Cell and Gene Therapy at Risk From Trump Tariffs, Industry Says
In comments posted in response to the Trump administration’s pharma tariff investigation, companies and industry groups offered solutions to ease the impacts if the plan must go ahead.
June 3, 2025
 · 
4 min read
 · 
Annalee Armstrong
Fantasy background for poster for tourism company. Illustration of stormy sea waves with ancient sailboat Spanish galleon and lighthouse at night. Modern print. Vector cartoon image.
Obesity
Amid Rough Waters, Regeneron Puts Nearly $2B on the Line For Chinese Obesity Drug
Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.
June 2, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Pictured: Abstract handshake
Mergers & acquisitions
Sanofi Inks $9.5B Blueprint Buyout to Expand Rare Disease Portfolio
Blueprint has a next-generation systemic mastocytosis treatment, called elenestinib, that Sanofi CEO Paul Hudson told analysts provides an “opportunity to grow through the ‘30s.”
June 2, 2025
 · 
3 min read
 · 
Nick Paul Taylor
Photos of a Bristol Myers Squibb building and a BioNTech flag
Deals
BMS Commits up to $11B+ To Work With BioNTech on Solid Tumor Bispecific
Bristol Myers Squibb is dropping at least $3.5 billion to jointly develop the bispecific antibody, which will race with Summit Therapeutics, Merck and Pfizer in the crowded PD-1/PD-L1xVEGF space.
June 2, 2025
 · 
2 min read
 · 
David Adam
A human hand and a robot hand shake hands over a white circle on a green background
Artificial intelligence
AstraZeneca Racks Up AI Partners, Seeking To Stop Cancer at All Stages
AstraZeneca has put hundreds of millions of dollars into AI deals, with an eye toward not just accelerating the development of drugs that treat cancer after it appears but also in creating diagnostics that can catch cancer earlier than current methods allow.
June 2, 2025
 · 
4 min read
 · 
Dan Samorodnitsky
concept - kidney tumor.
Cancer
Arcus Kidney Cancer Drug Casdatifan Advances to Challenge Merck’s Welireg
Updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug secured approval for a type of kidney cancer in 2023.
June 2, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Start early or business advantage. Businessman starts running ahead of competitors vector
Cancer
Bicara Responds to Rival Merus With Early Survival Data at ASCO25
Following Merus’ splash last month with a “best-in-disease profile” for its head and neck cancer bispecific, Bicara touted positive results for its monocolonal antibody, but analysts say Merus still has the upper hand.
June 2, 2025
 · 
2 min read
 · 
David Adam
Pictured: Facade of Moderna's building in Massachusetts
Vaccines
Moderna Wins FDA Approval for Next-Gen COVID-19 Vaccine Despite ‘Investor Nervousness’
Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the FDA’s attitude toward mRNA and COVID-19 vaccines that have investors worried.
June 2, 2025
 · 
3 min read
 · 
Nick Paul Taylor
Legal and law concept illustration stock illustration
Policy
Post-Chevron Legal Battles: Three Key Cases to Watch
The overturning of the FDA’s lab-developed tests rule is just the tip of the iceberg. With the loss of Chevron deference, power has shifted from federal agencies to the courts, with potential implications for everything from the FDA shortage list to CMS drug price negotiations.
June 2, 2025
 · 
7 min read
 · 
Ben Hargreaves
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS